Technical Data Sheet
SS-31
Also Known As: Elamipretide, MTP-131, Bendavia, SS-31 peptide, Szeto-Schiller 31, D-Arg-dimethylTyr-Lys-Phe-NH2, Cardiolipin-targeting peptide, Mitochondria-targeted peptide, Mitochondrial protective peptide, Inner mitochondrial membrane peptide, Cardiac mitochondria peptide, Bendavia heart failure, SS31 Barth syndrome, mitochondrial targeting, cardiolipin
Scan To View Profile
| Evidence Tier | Approved Drug |
|---|---|
| Category | Anti-Aging & Longevity |
| Class | Mitochondria-targeted tetrapeptide (D-Arg-dimethylTyr-Lys-Phe-NH2); cardiolipin-targeting |
| Molecular Target | Cardiolipin on inner mitochondrial membrane; scavenges mitochondrial ROS; stabilizes cristae architecture; restores respiratory chain efficiency |
| Sequence | D-Arg-Dmt-Lys-Phe-NH2 |
| Molecular Weight | ~639.8 Da |
| CAS | 736992-21-5 |
| Parent | Szeto-Schiller peptide series |
| Mechanism | It specifically binds to cardiolipin, a vital fat found on the inner wall of the mitochondria. This instantly restores the structural integrity of the cell's energy factory, improving ATP output. |
| Studied For | Primary mitochondrial disease, Barth syndrome (cardiolipin deficiency), Heart failure / ischemia-reperfusion injury, Dry AMD (age-related macular degeneration), Mitochondrial aging, Cardiac energetics, Skeletal muscle mitochondria, Kidney ischemia-reperfusion models, ROS reduction at mitochondria, Cardiolipin stabilization, Respiratory chain Complex I-V efficiency, ATP production enhancement, Frailty / aging mitochondria, Chronic kidney disease models, Neurodegenerative disease mitochondria, Exercise intolerance research, energy production, anti-aging, mitochondrial repair, heart failure, cognitive decline, ischemia reperfusion, kidney protection |
| Administration Route | Injection Only |
| Form | lyophilized |
| Diluent | sterile or bacteriostatic water |
| Storage Temperature | cold, dark; avoid freeze-thaw |
| Light Sensitive | Yes |
| Freeze / Thaw | avoid |
| Reconstituted Shelf Life | 28 Days |
| Handling Notes | Non-natural residues improve stability. |
| Regulatory | FDA accelerated approval 19 September 2025 as Forzinity (elamipretide hydrochloride) to improve muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kg; 40 mg subcutaneous once daily. Holds FDA Orphan Drug, Fast Track, Priority Review and Rare Pediatric designations, and an EMA Orphan Drug designation for Barth syndrome. No EMA marketing authorization identified as of August 2026. All other uses remain investigational. Not on the WADA 2026 Prohibited List. |
| Sources |